BBLG: צמיחה צפויה ברווח למניה לשנה הבאה bonebiologics.com

Bone Biologics develops proteins for bone regeneration, which will ensure high margins during mass production. The trend in consensus EPS forecasts for the coming year clearly demonstrates market expectations, where the value of 50.50 serves as the current metric. Growth is driven by rhBMP-2 trials in Australia and an aging population, although the lack of revenue during the research stage temporarily increases unit costs for patents.

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety, as it measures market expectations for future returns and the stability of the fundamental trend. For Bone Biologics (BBLG), the current consensus EPS growth forecast for next year reflects the probability of commercial success for bone regeneration proteins and the speed of obtaining regulatory approvals for spinal fusion.